Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Docetaxel for Recurrent Head and Neck Cancer
NCT02110992Phase 1Terminated
- Sponsor
- University of Cincinnati
- Start
- Apr 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of docetaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Cincinnati. Primary endpoint: Number of acute dose limiting toxicities at 3 months. Started Apr 2014; status: terminated.
02
Drugs
docetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02110992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110992.